Journal article
Irbesartan in Patients with Atrial Fibrillation
Abstract
BACKGROUND: The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk.
METHODS: We randomly assigned patients with a history of risk factors for stroke and a systolic blood pressure of at least 110 mm Hg to receive either irbesartan at a target dose of 300 mg once daily or double-blind placebo. These patients were already enrolled …
Authors
Yusuf S; Healey JS; Pogue J; Chrolavicius S; Flather M; Hart RG; Hohnloser SH; Joyner CD; Pfeffer MA; Connolly SJ
Journal
The New England Journal of Medicine, Vol. 364, No. 10, pp. 928–938
Publisher
Massachusetts Medical Society
Publication Date
March 10, 2011
DOI
10.1056/nejmoa1008816
ISSN
0028-4793